Your browser doesn't support javascript.
loading
Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.
Song, Yan; Wang, Jinwan; Ren, Xiubao; Jin, Jie; Mao, Li; Liang, Chris; Ding, Lieming; Yang, Lin.
Afiliação
  • Song Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Wang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Ren X; Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
  • Jin J; Department of Urology, Peking University First Hospital, Beijing 100034, China.
  • Mao L; Betta Pharmaceuticals Co., Ltd., Hangzhou 311100, China.
  • Liang C; Betta Pharmaceuticals Co., Ltd., Hangzhou 311100, China.
  • Ding L; Betta Pharmaceuticals Co., Ltd., Hangzhou 311100, China.
  • Yang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Chin J Cancer Res ; 33(1): 103-114, 2021 Feb 28.
Article em En | MEDLINE | ID: mdl-33707933
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China